



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
**29.08.2001 Bulletin 2001/35**

(51) Int Cl.7: **C07C 219/26, C07D 207/337,**  
**A61K 31/24**

(21) Application number: **99953994.3**

(86) International application number:  
**PCT/ES99/00352**

(22) Date of filing: **04.11.1999**

(87) International publication number:  
**WO 00/27799 (18.05.2000 Gazette 2000/20)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

- **CHALAUX FREIXA, Maria**  
**E-08025 Barcelona (ES)**
- **HUGUET CLOTET, Joan**  
**E-08970 Sant Joan Despi (ES)**
- **MOURELLE MANCINI, Marisabel**  
**E-08028 Barcelona (ES)**
- **DE RAMON AMAT, Elisabet**  
**E-08035 Barcelona (ES)**

(30) Priority: **06.11.1998 ES 9802329**

(71) Applicant: **VITA-INVEST, S.A.**  
**E-08970 Sant-Joan-Despi (ES)**


(74) Representative: **Ponti Sales, Adelaida et al**  
**Consell de Cent 322**  
**08007 Barcelona (ES)**

(72) Inventors:  
• **DEL CASTILLO NIETO, Juan Carlos**  
**E-08025 Barcelona (ES)**

(54) **NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS**

(57) New esters derived from substituted phenyl cyclohexyl compounds, which are derived from Tramadol, process for obtaining them and their use for preparing

a drug with analgesic properties. These new compounds of general formula (I) have a higher analgesic activity, a lower toxicity and a longer effective time period than Tramadol.




**Description****Field of the invention**

**[0001]** The present invention relates to new esters derived from substituted phenyl-cyclohexyl compounds, which are derived from Tramadol. The obtained compounds have a higher analgesic activity, a lower toxicity and a longer effective time period than Tramadol.

**Background of the invention**


**[0002]** The treatment of pain is of great importance in the > field of medicine. The pharmacological agents presently used for the treatment of pain can be primarily classified into two large groups: opioid compounds and non-steroidal anti-inflammatories (NSAIs). The NSAIs are only useful in the case of light or moderate pain; severe pain has traditionally been treated with opioid compounds. However, these opioid compounds have several undesirable side effects, such as constipation, respiratory depression, tolerance and possibility of addiction.

**[0003]** US patent 3652589 describes a type of analgesic compounds with a structure of substituted cycloalkanol phenol ethers having a basic amino group in the cycloalkyl ring. Among them the (1R, 2R or 1S, 2S)-2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol compound, generally known as Tramadol, is specially noted and specifically claimed in said patent.




Tramadol

**[0004]** A series of products derived from the above, in which the dehydration in the cycloalkanol ring has occurred together with the demethylation of the methoxyl in the 3 position of the phenyl ring, of structure:



have been described in the Dutch patent NL 6610022.

**[0005]** This patent also describes products derived from those of said US patent, in which the methoxyl group in the 3 position of the phenyl ring has been demethylated. That is, products of structure:



[0006] O-demethyltramadol is included among those products described in this patent, said product having been described as one of the metabolization products of Tramadol (Von W. Lintz et al. *Arzneim-Forsch (Drug Res)* **31** (II); 1932-43 (1981). The analgesic activity of Tramadol is attributed to its (+) isomer (Lars Poulsen et al. *Clin. Pharmacol. Ther* (St. Louis) 1996, **60** (6), 636-644). However, there is no data as to the clinical use of the O-demethyltramadol metabolite.

[0007] More recently, in patent EP 753506, new derivatives of Tramadol have been described, which are O-demethylsubstituted, halogenated at position 1 and/or 3-cyclohexyl substituted.

[0008] Tramadol has an opioid agonist effect. However, the clinical experience with Tramadol shows that in spite of this, it does not present some of the side effects typical of the opioid agonists, such as respiratory depression (W. Vogel et al. *Arzneim. Forsch (Drug Res)* **28** (I), 183 (1978)), constipation (I. Arend et al. *Arzneim. Forsch (Drug Res)* **28** (I), 199 (1978), tolerance (L. Flohe et al., *Arzneim. Forsch (Drug Res)* **28** (I), 213 (1978)) and possibility of abuse (T. Yenagita et al., *Arzneim. Forsch (Drug Res)* **28** (I), 158 (1978)). Some side effects specific for Tramadol have been found, which are caused when it is injected intravenously (i.v.) and quickly, such as hot flushes and sweating.

[0009] Another of the disadvantages associated with Tramadol is its short effective time period (T. Matthiesen, T. Wohrmann, T.P. Coogan, H. Uragg, "The experimental toxicology of tramadol: an overview", *Toxicology Letters* **95**, 63-71, (1998)).

[0010] Based on the above background of the invention, the compounds with an analgesic activity similar to or higher than that of Tramadol and with a lower toxicity and with a higher effective time period are still of interest.


### Description of the invention

[0011] The present invention relates to new esters of O-demethyltramadol or its 1,2-dehydrated derivative.

[0012] The analgesic activity of these compounds has been found to be higher than that of Tramadol with a lower toxicity and a longer effective time period when administered orally (see Figure 1).

[0013] In particular, the present invention describes and claims those products of general formula (I), its salts and optical isomers, as well as the process for obtaining them.




[0014] The products of the present invention are represented by the following general formula (I):



(I)

\* Shows possibility of asymmetric carbons

where R<sub>1</sub> is:



A

B

or

C

$R_2$  is: OH;

$R_3$  is: H;

or  $R_2$  and  $R_3$  together form a double bond;

$R_4$  is: H or C<sub>1</sub>-C<sub>3</sub> alkyl;

$R_5$  is: H, NH<sub>2</sub>, NH-R<sub>11</sub> or O-R<sub>11</sub>;

$R_6$  is: H, CO-R<sub>11</sub>, O-R<sub>11</sub> or halogen;

$R_7$  is: H, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> O-alkenyl, phenyl,

or  $R_6$  and  $R_7$  are -CH=CR<sub>12</sub>-CR<sub>13</sub>=CH-, forming an optionally substituted condensed aromatic ring;

$R_8$  is: OH, -O-CO-N(CH<sub>3</sub>)<sub>2</sub> or NH-R<sub>11</sub>;

$R_9$  and  $R_{10}$  are: H or C<sub>1</sub>-C<sub>4</sub> alkyl, whether equal or different,

or form a -CH<sub>2</sub>-CH<sub>2</sub>- bond;

$R_{11}$  is: phenyl; phenyl optionally substituted by 1 or more of the following substituents: halogen (Cl, Br, I), NO<sub>2</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, OH, or NH;

$R_{12}$  and  $R_{13}$  are: H, or C<sub>1</sub>-C<sub>6</sub> O-alkyl, whether equal or different.

**[0015]** When  $R_1$  is A, preferably,  $R_4$  is methyl or H,  $R_5$  is NH<sub>2</sub>, 2,5-dichlorophenylamino or H,  $R_6$  is substituted CO-phenyl or H,  $R_7$  is isobutyl or H, or  $R_6$  and  $R_7$  form a substituted condensed aromatic ring.

**[0016]** More preferably, when  $R_1$  is A, the products are:

- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-(4-isobutyl-phenyl)-propionate
- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(4-isobutyl-phenyl)-propionate
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate

**[0017]** When  $R_1$  is B, preferably,  $R_8$  is OH or -O-CO-N(CH<sub>3</sub>)<sub>2</sub>.

**[0018]** More preferably, when  $R_1$  is B, the products are:


- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-hydroxybenzoate
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-hydroxybenzoate
- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-dimethylcarbamoyloxy-benzoate
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-dimethylcarbamoyloxy-benzoate.

**[0019]** When  $R_1$  is C, preferably,  $R_9$  is methyl or H or forms a -CH<sub>2</sub>-CH<sub>2</sub>- bond with  $R_{10}$ . More preferably, when  $R_1$  is C, the products are:


- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate

## DESCRIPTION OF THE METHODS

**[0020]** The compounds of general formula (I) of the present invention can be obtained by a general process which is characterised by reacting a compound of general formula (II) with the corresponding acid or acid derivative of general formula III.



Where  $R_1$ ,  $R_2$ ,  $R_3$  have the above defined meaning, and  $L = OH$ , halogen,



O- $R_{14}$  or -CO- $R_{15}$   
being

$R_{14} = C_{1-6}$  alkyl, phenyl, optionally substituted phenyl, and

$R_{15} =$  alkyl, a phenyl ring optionally substituted by one or more substituents or a heterocyclic ring optionally substituted by one or more substituents.

[0021] Preferably  $L$  is  $OH$  or halogen.

[0022] The reaction is carried out in an inert solvent, preferably dichloromethane, tetrahydrofuran, etc., in a temperature range of  $-20^\circ$  to  $120^\circ C$ , preferably a range of  $0^\circ$  to  $35^\circ C$ , and preferably in the presence of a condensation promoting agent, such as carbonyldiimidazol, dicyclohexylcarbo-diimida, etc.

[0023] The compounds of formula (II) are obtained according to the methods disclosed in the literature (NL 6610022 or Flick *et al. Arzneim. Forsch/Drug Res.* (1978), **28** (I), 107-113).

## Description of the pharmacological processes

### Analgesic Activity Tests

[0024] The pharmacological activity of the products of the present invention was tested *in vivo* in several experimental models, which are known to evaluate the pain in animals.

#### a) Hot plate method

[0025] The method that was used is described by Eddy N.B. and Leimbach D. (J. Pharm. Exp. Ther. **107**: 385-393, 1953). The analgesic effect of the products was evaluated analysing the behaviour of the animals on a hot surface at  $55^\circ C \pm 1^\circ C$ .

[0026] Male Swiss mice weighing 20-25 g were used. The compounds being tested were administered orally or intraperitoneally 1 hour or 30 minutes before starting the test, respectively.

[0027] The process consisted of placing the animals on the plate and keeping them in a Plexiglas cylinder 25 cm high and 21 cm high. The time the animals took to jump off the hot surface was determined. The animals were selected before starting the test so that those that took longer than 10 seconds to jump off were not included in the group that would receive treatment.

[0028] 30 minutes after administering the product being tested, the test was repeated and the maximum time it took the animals to jump off was again recorded. Those animals that did not jump off after 60 seconds were removed from the plate to avoid any injuries and were recorded as 100 protection.

[0029] The results are expressed as the of jump time increase calculated as follows:

$$\% \text{jump time increase} = \frac{(\text{treated jump time} - \text{base jump time})}{\text{base jump time}} \times 100$$

[0030] In order to determine the duration of the analgesic effect of the orally administered products, the analgesic activity was evaluated on the hot plate 1, 3, 6, 8, and 24 hours after the administration of the product, as well as the control group which received treatment only with the vehicle. The base responses were evaluated at 30 and 5 minutes prior to administering the products.

#### b) Determination of the DL50 in the products.

[0031] (EUDRA/S/87/011, *Single Dose Toxicity*, European Directive 75/318/EEC) (ICH S4, Toxicity Studies, single dose and repeated dose, CPMP vol III Feb. 57, *Single dose toxicity*)

[0032] Male Swiss mice of the same batch weighing 20-25 g are used in order to estimate the acute toxicity of the products.

[0033] Prior to administering the products, the animals were forced to fast for 12 hours with no intake of food but free access to water. Several subgroups of 10 animals were randomly selected and orally given increasing doses of the products in single administration, after which they remained under observation for a period of 14 days with free access to water and food. Finally, the number of dead animals of each subgroup was quantified and the value of the DL50 was calculated (1-2).

#### Description of the figure

[0034] Figure 1 shows the analgesic effect on the hot plate test with mice in terms of time, expressed as percentage of increased response time with relation to the time (in hours) elapsed since the administration of the product. It is represented in grey for Tramadol, striped for compound (I) of example 6 and in black for example 1.


### EXPERIMENTAL PART

#### 1.1. Synthesis examples

##### EXAMPLE 1

##### *Synthesis of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)-phenyl 2-(4-isobutyl-phenyl)-propionate*

[0035]



[0036] 0.76 g (4.8 mmol) of carbonyldiimidazol were added to 1 g (4.8 mmol) of (±)-Ibuprofen in 60 ml of dry THF. The reaction was kept at room temperature for 2 h, after which a 60% solution of 0.59 g (2.4 mmol) of (RR,SS)-3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenol previously treated with 0.1 g (2.5 mmol) of sodium hydride in mineral oil was added.

[0037] The reaction was left at room temperature for 16 h. It was concentrated to dryness and the residue was treated with 100 ml of dichloromethane and washed with 2 x 50 ml of NaOH 1N and then with 100 ml of H<sub>2</sub>O.


[0038] The organic phase was dried and concentrated and the residue was chromatographed on silica gel. By eluting with CH<sub>2</sub>Cl<sub>2</sub>/EtOH 98/2 to 96/4, 0.65 g (62%) of pure product was obtained as a colourless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.90 (d, 6H); 1.20-2.20 [m, 21H including 1.6 (d, 3H) and 2.05 (s, 6H)]; 2.32-2.44 (d.d, 1H); 2.47 (d, 2H); 3.92 (c, 1H) ; 6.78-6.86 (m, 1H); 7.12 (d, 2H) ; 7.18 (s.a., 1H) ; 7.22-7.34 (m, 4H).

**EXAMPLE 2**

**Synthesis of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate**

[0039]




[0040] Following the process described in example 1 and substituting the (±)-Ibuprofen with (+)-6-methoxy-α-methyl-2-naphthylacetic acid (Naproxen) the title product is obtained as an oil with a 40% yield.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 1.20-2.20 [m, 20 H including 1.67 (d, 3H,) and 2.06 (s, 6H)]; 2.35 (dd, 1H); 3.91 (s, 3H); 4.09 (c, 1H) ; 6.75-6.85 (m, 1H); 7.00 (s.a., 1H); 7.15-7.35 (m, 4H); 7.50 (d.d, 1H); 7.70-7.80 (m, 3H).

**EXAMPLE 3**

**Synthesis of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)-phenyl 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate**

[0041]




[0042] Following the process described in example 1 and substituting the (±)-Ibuprofen with (±) ketorolac (5-benzoyl-1,2-dihydro-1H-pyrrolizine-1-carboxylic acid) the title product is obtained as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.20-2.20 (m, 17H); 2.40 (d.d, 1H); 2.80-3.10 (m, 2H); 4.28-4.72 (m, 3H); 6.26 (d, 1H); 6.87 (d, 1H); 6.90-6.98 (m, 1H); 7.30-7.60 (m, 6H); 7.78-7.88 (m, 2H)

**EXAMPLE 4****Synthesis of 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(4-isobutyl-phenyl)-propionate**

[0043]




[0044] Following the process described in example 1 and substituting the (RR,SS)-3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenol with 3-(2-dimethylaminomethyl-1-cyclohex-1-enyl)-phenol the title product is obtained as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.90 (d, 6H); 1.60 (d, 3H); 1.62-1.98 (m, 4H); 2.02 (s, 6H); 2.10-2.25 (m, 4H); 2.45 (d, 2H); 2.70 (s, a., 2H); 3.92 (c, 1H); 6.70 (d, 1H); 6.82-6.90 (m, 2H); 7.12 (d, 2H); 7.20-7.32 (m, 3H).

**EXAMPLE 5****Synthesis of 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate**

[0045]




[0046] Following the process described in example 1 and substituting the (±)-Ibuprofen with (+)-6-methoxy-α-methyl-2-naphthalenacetic acid (Naproxen) and the (RR,SS)-3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenol with 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenol the title product is obtained as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.60-1.76 (m, 4H); 1.68 (d, 3H); 2.02 (s, 6H); 2.10-2.24 (m, 4H); 2.66 (s, 2H); 3.92 (s, 3H); 4.09 (c, 1H); 6.70 (d, 1H); 2.82-2.92 (m, 2H); 7.12-7.28 (m, 3H); 7.50 (dd, 1H); 7.70-7.78 (m, 3H).



**EXAMPLE 6****3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl (RR-SS)-2-hydroxybenzoate**

[0047]




[0048] To a solution of 7.3 g (29.3 mmol) of (RR-SS)-3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)-phenol and 2.6 g (32.5 mmol) of pyridine in 50 ml of CH<sub>2</sub>Cl<sub>2</sub> a 5.8 g (29.3 mmol) solution of acetylsalicyloyl chloride in 50 ml of CH<sub>2</sub>Cl<sub>2</sub> was added dropwise at 0°C. The mixture was kept at 0°C for 10 h, 100 ml of methanol and 100 ml of HCl 1N were added and it was kept at 25°C for 4 days. After evaporating the methanol and basifying to pH 8.5 with Na<sub>2</sub>CO<sub>3</sub>, it was extracted with EtOAc (3 x 50 ml). The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated, and the residue was purified by silica gel chromatography, by eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 1000:30:3, to obtain 1.7 g (16%) of the title compound as a yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.20-2.25 (m, 16H) including 2.11 (s, 6H); 2.45 (dd, 1H); 6.90-7.15 (m, 3H); 7.30-7.48 (m, 3H); 7.48-7.62 (m, 1H); 8.08 (dd, 1H); 10.55 (s, 1H, exchange with D<sub>2</sub>O)

**EXAMPLE 7****3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-hydroxybenzoate**

[0049]




[0050] Starting from 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenol and following the process described in example 6, the title compound was obtained as a yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.60-1.80 (m, 4H); 2.10 (s, 6H); 2.15-2.35 (m, 4H); 2.75 (s, 2H); 6.90-7.10 (m, 5H); 7.40 (t, 1H); 7.55 (t, 1H); 8.10 (d, 1H); 10.50 (sa, 1H, exchange with D<sub>2</sub>O).

**EXAMPLE 8****3- (2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl (RR-SS)-2-dimethylcarbamoyloxy-benzoate**

[0051]




[0052] A solution of 1.82 g (8.0 nmol) of 2-dimethylcarbamoyloxybenzoyl chloride in 25 ml of CH<sub>2</sub>Cl<sub>2</sub> was added dropwise at 0°C to a solution of 1.9 g (7.7 nmol) of (RR-SS)-3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)-phenol and 0.73 g (9.2 nmol) of pyridine in 50 ml of CH<sub>2</sub>Cl<sub>2</sub>. The mixture was maintained at 0° for 10 h, and poured over frozen water, the phases were separated and the aqueous phase was extracted with 100 ml of CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was dried (MgSO<sub>4</sub>) and evaporated. The residue was chromatographed on silica gel by eluting with CH<sub>2</sub>Cl<sub>2</sub>/acetone 80:20. 570 mg (48%) of the title compound was obtained as an orange oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.30-1.90 (m, 9H) ; 2.05 (m, 1H) ; 2.10 (s, 6H) ; 2.45 (dd, 1H) ; 2.95 (s, 3H) ; 3.05 (s, 3H) ; 7.00-7.10 (m, 1H) ; 7.20 (d, 1H) ; 7.30-7.40 (m, 4H) ; 7.60 (t, 1H) ; 8.15 (d, 1H).

**EXAMPLE 9****3- (2-dimethylaminomethyl-cyclohex-1-enyl) -phenyl 2-dimethylcarbamoyloxy-benzoate**

[0053]



[0054] Starting from 925 mg (4.0 mmol) of 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenol and following the process described in example 8, 190 mg (32%) of the title compound was obtained as a yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.70 (m, 4H) ; 2.07 (s, 6H) ; 2.10-2.30 (m, 4H) ; 2.75 (s, 2H) ; 2.95 (s, 3H) ; 3.10 (s, 2H) ; 6.90 (s, 1H) ; 6.95 (d, 1H) ; 7.05 (d, 1H) ; 7.20 (d, 1H) ; 7.30-7.45 (m, 2H) ; 7.65 (t, 1H) ; 8.20 (d, 1H).

**Examples of pharmacological results**

[0055] Table 1 below shows the results of the pharmacological activity of several examples of the invention product, as well as Tramadol. The results are expressed as percentage of increased response time on the hot plate test.

[0056] Table 2 shows the acute toxicity figures of Tramadol and of examples of the invention product, where the lower toxicity of the latter can be observed.

# EP 1 127 871 A1

Analgesic activity in mice of the products on the hot plate

[0057]

TABLE 1


PRODUCT (15 mg/kg, intraperitoneal adm.)	% response time increase (n = 20)
<b>Tramadol</b>	218±98
EXAMPLE 1	568±100
EXAMPLE 2	539±50
EXAMPLE 3	416±146
EXAMPLE 4	333±134
EXAMPLE 5	356±151
EXAMPLE 6	546±63
EXAMPLE 7	634±42
EXAMPLE 8	327±65
EXAMPLE 9	405±13

TABLE 2

PRODUCT (20 µmol/kg, oral adm.)	% response time increase on hot plate (n= 20-40)	DL50 approx. (mg/kg) Oral adm.
<b>TRAMADOL</b>	87±23	350
EXAMPLE 6	248±72	550
EXAMPLE 1	210±88	900




## Claims

- Compound of general formula (I) :



(I)

where R is:



A

B

or

C

R<sub>2</sub> is: OH;

R<sub>3</sub> is: H

or R<sub>2</sub> and R<sub>3</sub> together form a double bond;

R<sub>4</sub> is: H or C<sub>1</sub>-C<sub>3</sub> alkyl;

R<sub>5</sub> is: H, NH<sub>2</sub>, NH-R<sub>11</sub> or O-R<sub>11</sub>;

R<sub>6</sub> is: H, CO-R<sub>11</sub>, O-R<sub>11</sub> or halogen;

R<sub>7</sub> is: H, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> O-alkenyl, phenyl,

or R<sub>6</sub> and R<sub>7</sub> are -CH=CR<sub>12</sub>-CR<sub>13</sub>=CH-, forming an optionally substituted condensed aromatic ring;

R<sub>8</sub> is: OH, -O-CO-N(CH<sub>3</sub>)<sub>2</sub> or NH-R<sub>11</sub>;

R<sub>9</sub> and R<sub>10</sub> are: H or C<sub>1</sub>-C<sub>4</sub> alkyl, whether equal or different,

or form a -CH<sub>2</sub>-CH<sub>2</sub>- bond;

R<sub>11</sub> is: phenyl; phenyl optionally substituted by 1 or more of the following substituents: halogen (Cl, Br, I), NO<sub>2</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, OH, or NH<sub>2</sub>;

R<sub>12</sub> and R<sub>13</sub> are: H, or C<sub>1</sub>-C<sub>3</sub> O-alkyl, whether equal or different; its salts and optical isomers.

2. Compound as claimed in claim 1, **characterised in that** R<sub>1</sub> is A, and R<sub>4</sub> is methyl or H, R<sub>5</sub> is NH<sub>2</sub>, 2,5-dichlorophenylamino, or H, R<sub>6</sub> is substituted CO-phenyl or H, R<sub>7</sub> is isobutyl or H, or R<sub>6</sub> and R<sub>7</sub> form a substituted condensed aromatic ring.

3. Compound as claimed in claim 1, **characterised in that** R<sub>1</sub> is B, and R<sub>8</sub> is OH or -O-CO-N(CH<sub>3</sub>)<sub>2</sub>.

4. Compound as claimed in claim 1, **characterised in that** R<sub>1</sub> is C, and R<sub>9</sub> is methyl or H, or forms a -CH<sub>2</sub>-CH<sub>2</sub>- bond with R<sub>10</sub>, and R<sub>11</sub> is phenyl or tolyl.

5. Compound as claimed in claim 2, **characterised in that** it is selected from one of the following:

- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-(4-isobutyl-phenyl)-propionate;
- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate;
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(4-isobutyl-phenyl)-propionate;
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate;


6. Compound as claimed in claim 3, **characterised in that** it is selected from one of the following:

- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-hydroxybenzoate;
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-hydroxybenzoate;
- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-dimethylcarbamoyloxy-benzoate;
- 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-dimethylcarbamoyloxy-benzoate.


7. Compound as claimed in claim 4, **characterised in that** it is selected from one of the following:

- 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate.

8. Process for obtaining a compound as claimed in claim 1, **characterised in that** a compound of formula (II) is reacted with a compound of formula (III):



II



III


where:

$R_2 = OH$

$R_3 = H$

or  $R_2$  and  $R_3$  together form a double bond;

$X = OH$ , halogen,




$O-R_{14}$  or  $-CO-$


$R_{14} = C_{1-6}$  alkyl, phenyl, optionally substituted phenyl, and

$R_{15} =$  alkyl, a phenyl ring optionally substituted by one or more substituents or a heterocyclic ring optionally substituted by one or more substituents;


$R_1$ :



A



B



C

$R_4$  is: H or  $C_1-C_3$  alkyl;

$R_5$  is: H,  $NH_2$ ,  $NH-R_{11}$  or  $O-R_{11}$  ;

$R_6$  is: H,  $CO-R_{11}$ ,  $O-R_{11}$  or halogen;

$R_7$  is: H,  $C_1-C_5$  alkyl,  $C_2-C_5$  O-alkenyl, phenyl,

or  $R_6$  and  $R_7$  are  $-CH=CR_{12}-CR_{13}=CH-$ , forming an optionally substituted condensed aromatic ring;

$R_8$  is: OH,  $-O-CO-N(CH_3)_2$  or  $NH-R_{11}$  ;

$R_9$  and  $R_{10}$  are: H or  $C_1-C_4$  alkyl, whether equal or different,

or form a  $-CH_2-CH_2-$  bond;

$R_{11}$  is: phenyl; phenyl optionally substituted by 1 or more of the following substituents: halogen (Cl, Br, I),  $NO_2$ ,

$C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl, OH, or  $NH_2$ ;

$R_{12}$  and  $R_{13}$  are: H, or  $C_1-C_3$  O-alkyl, whether equal or different;

in an inert solvent, in a temperature range of  $-20^\circ$  to  $120^\circ C$ , in the presence or absence of a condensation promoting agent.

**EP 1 127 871 A1**

9. Process as claimed in claim 8, **characterised in that** said inert solvent is dichloromethane or tetrahydrofuran.

10. Process as claimed in claim 8, **characterised in that** said condensation promoting agent is carbonyldiimidazol or dicyclohexylcarbo-diimida.

5

11. Process as claimed in claim 8, **characterised in that** said temperature range is from 0° to 35°C.

12. Use of a compound of general formula (I) as claimed in any of claims 1 to 7 for preparing a drug for the treatment of pain.

10

15

20

25

30


35

40

45

50

55



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/LS 99/00352

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07C219/26 C07D207/337 A61K31/24		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 733 936 A (BUSCHMANN HELMUT HEINRICH ET AL) 31 March 1998 (1998-03-31) claims 2,4,5; examples ---	1-12
A	GB 997 399 A (CHEMIE GRUNENTHAL GMBH) 7 July 1965 (1965-07-07) claims 2,7,8,15 ---	1-12
A	US 3 652 589 A (FLICK KURT ET AL) 28 March 1972 (1972-03-28) claims 2-23 ---	1-12
A	TAKESHI ET AL: "Synthesis and Analgesic Activity of Cyclohexenylmethylanines and Related Compounds" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 32, no. 6, 1984, pages 2279-2289, XP002900881 -----	1-12
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family		
Date of the actual completion of the international search  8 February 2000		Date of mailing of the international search report  21.03.2000
Name and mailing address of the ISA European Patent Office, P.B. 5618 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Elena Albarran

Form PCT/ISA/210 (second sheet) (July 1992)



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT, \_S 99/00352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5733936 A	31-03-1998	DE 19525137 A	16-01-1997
		AT 183495 T	15-09-1999
		AU 703890 B	01-04-1999
		AU 5945396 A	23-01-1997
		CA 2180816 A	12-01-1997
		CN 1146987 A	09-04-1997
		DE 59602775 D	23-09-1999
		EP 0753506 A	15-01-1997
		HU 9601884 A	29-12-1997
		JP 9031033 A	04-02-1997
		PL 315192 A	20-01-1997
		SI 753506 T	31-10-1999
-----			
GB 997399 A		BE 646062 A	02-10-1964
		CH 439273 A	
		DE 1199764 B	
		FI 42320 B	31-03-1970
		FR 3618 M	
		FR 1543914 A	
		NL 6403199 A,B	05-10-1964
		SE 300615 B	06-05-1968
-----			
US 3652589 A	28-03-1972	US 3830934 A	20-08-1974
-----			